Sutro Biopharma Inc (NASDAQ:STRO) Expected to Post Earnings of -$0.70 Per Share

Analysts forecast that Sutro Biopharma Inc (NASDAQ:STRO) will report earnings of ($0.70) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Sutro Biopharma’s earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.83). The firm is expected to issue its next earnings results on Monday, April 6th.

According to Zacks, analysts expect that Sutro Biopharma will report full year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($2.62) to ($2.35). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.93) per share, with EPS estimates ranging from ($3.59) to ($2.44). Zacks’ EPS averages are an average based on a survey of analysts that follow Sutro Biopharma.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. The business had revenue of $12.28 million for the quarter, compared to analysts’ expectations of $8.88 million.

Several research firms have recently weighed in on STRO. BTIG Research began coverage on Sutro Biopharma in a research report on Monday, October 7th. They issued a “buy” rating and a $19.00 target price on the stock. Wedbush restated an “outperform” rating on shares of Sutro Biopharma in a research report on Wednesday, October 30th. Zacks Investment Research downgraded Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 17th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Sutro Biopharma in a research report on Monday, October 21st. Finally, ValuEngine downgraded Sutro Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $19.40.

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its position in Sutro Biopharma by 1,365.7% during the second quarter. Acadian Asset Management LLC now owns 9,058 shares of the company’s stock worth $103,000 after buying an additional 8,440 shares in the last quarter. Wells Fargo & Company MN lifted its position in Sutro Biopharma by 240.7% during the second quarter. Wells Fargo & Company MN now owns 11,484 shares of the company’s stock worth $130,000 after buying an additional 8,113 shares in the last quarter. Rhumbline Advisers lifted its position in Sutro Biopharma by 9.3% during the third quarter. Rhumbline Advisers now owns 13,578 shares of the company’s stock worth $123,000 after buying an additional 1,156 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sutro Biopharma by 72.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 22,592 shares of the company’s stock worth $258,000 after buying an additional 9,482 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Sutro Biopharma by 104.8% during the second quarter. Bank of New York Mellon Corp now owns 30,472 shares of the company’s stock worth $347,000 after buying an additional 15,591 shares in the last quarter. Hedge funds and other institutional investors own 51.63% of the company’s stock.

Shares of NASDAQ STRO traded up $0.12 during midday trading on Monday, hitting $10.58. The stock had a trading volume of 62,700 shares, compared to its average volume of 39,201. The company has a market capitalization of $242.68 million, a PE ratio of -1.73 and a beta of 1.05. The stock has a 50 day simple moving average of $10.10 and a 200-day simple moving average of $10.40. Sutro Biopharma has a 1 year low of $7.69 and a 1 year high of $12.49.

About Sutro Biopharma

Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

See Also: Outperform Rating

Get a free copy of the Zacks research report on Sutro Biopharma (STRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.